Ecnoglutide Phase 3 results published in The Lancet

A Phase 3 trial of ecnoglutide has been published in The Lancet, reporting efficacy and safety results in adults with overweight or obesity. The study, described as a multicentre, randomised, double-blind, placebo-controlled trial, adds ecnoglutide to the growing list of GLP-1 receptor agonists with late-stage clinical evidence.

What makes ecnoglutide different?

Ecnoglutide is described as a 'biased' GLP-1 receptor agonist. This means it preferentially activates certain intracellular signalling pathways — specifically偏向 G protein signalling over β-arrestin recruitment. The rationale is that this bias may lead to improved efficacy and tolerability compared to unbiased GLP-1 agonists like semaglutide.

For a detailed profile of ecnoglutide's mechanism, see our ecnoglutide compound profile.

The biased agonism concept

Biased agonism (also called functional selectivity) is a pharmacological concept where a ligand stabilises a receptor conformation that preferentially activates one signalling pathway over another. In the context of GLP-1 receptors:

  • G protein signalling is associated with insulin secretion and glucose control
  • β-arrestin recruitment is associated with receptor desensitisation and internalisation

The hypothesis is that by favouring G protein signalling, biased agonists may provide sustained efficacy with reduced receptor desensitisation, potentially leading to better glycaemic control and weight loss with fewer side effects.

Clinical context

The GLP-1 agonist landscape has become increasingly competitive:

  • Semaglutide (Wegovy, Ozempic) remains the market leader for obesity and type 2 diabetes
  • Tirzepatide (Mounjaro, Zepbound) — a dual GIP/GLP-1 agonist — has demonstrated superior weight loss in head-to-head trials (SURMOUNT-5)
  • Retatrutide — a triple GIP/GLP-1/glucagon agonist — recently reported strong Phase 3 TRIUMPH-1 results
  • Orforglipron — an oral GLP-1 agonist — has matched injectable weight loss in Phase 3 ACHIEVE-1

Ecnoglutide's differentiation lies in its biased agonism approach, which is mechanistically distinct from adding additional receptor targets (GIP, glucagon) as seen with tirzepatide and retatrutide.

Implications for peptide research

The publication of ecnoglutide Phase 3 data in a high-impact journal like The Lancet is significant for several reasons:

  1. Proof of concept for biased agonism: The results provide clinical evidence for the biased agonism approach in GLP-1 therapeutics, a concept that has been primarily theoretical.

  2. Mechanistic diversity: Alongside multi-receptor agonists (tirzepatide, retatrutide) and oral formulations (orforglipron, danuglipron), biased agonism represents another axis of innovation in the GLP-1 space.

  3. Pipeline depth: The sheer number of GLP-1 agonists reaching Phase 3 underscores the intensity of competition in this therapeutic area.

UK regulatory context

Ecnoglutide is not approved by the MHRA and remains an investigational compound. As a research peptide, it is not a licensed medicine in the UK. NICE has recommended tirzepatide for obesity on the NHS (TA1026), but no similar appraisal exists for ecnoglutide given its earlier developmental stage.

Looking ahead

Key questions following this Phase 3 publication include:

  • Whether regulatory filings will be submitted based on these data
  • How ecnoglutide's efficacy and tolerability compare head-to-head with existing GLP-1 agonists
  • Whether the biased agonism mechanism translates to meaningful clinical advantages in real-world use

The GLP-1 peptide field continues to produce significant clinical data at an extraordinary pace, with 2025–2026 seeing multiple Phase 3 readouts across multiple mechanistic approaches.

This article is for research and educational purposes only. Ecnoglutide is an investigational compound and is not approved for human use. Nothing in this article constitutes medical advice.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.